As the pharmaceutical sector continues to evolve, the landscape of sales-driving indications is set to undergo transformation by 2030. In this article In Vivo delves into the therapeutic areas poised for substantial expansion and examines the strategic activities of leading companies within these burgeoning fields, providing an overview of how industry giants are positioning themselves to capitalize on these opportunities.
The biopharmaceutical industry is expected to witness growth of over two trillion dollars in sales between 2023 and 2030, according to Evaluate consensus forecasts. Sixty percent of these new sales are allocated to the top 20 indications by dollar growth over the period
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?